CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,395 enrolled
Drug / intervention
Neuraxial Analgesia +7 moredrug
Likely dose
Ondansetron 4 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04606264
NCT04606264Phase 3Completed
CompareCT.gov

Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)

Jennifer Holder-Murray·interventional·Posted Oct 28, 2020·Updated May 28, 2026

In Brief

A Phase 3 clinical trial evaluating Neuraxial Analgesia, Regional Block 1: Paravertebral, and 6 other interventions for Perioperative Optimization. Completed, enrolled 3,395 participants across 3 sites.

Detailed Summary

This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatments before, during and after surgery in all patients with elective surgical encounters at UPMC who meet eligibility criteria. The ERP domain seeks to enhance recovery by optimizing strategies of perioperative care through evaluating combinations of perioperative treatment, which consists of preoperative, intraoperative and postoperative care. Optimal combinations of perioperative care will be generated and analyzed to determine the best outcomes for patients as defined by reduction in hospital free days, reduction in postoperative nausea and vomiting, and improved pain control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerioperative Optimization
CountriesUnited States
CollaboratorsBerry Consultants

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedOct 28, 2020
Enrollment StartMay 15, 2023
Primary CompletionMar 21, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.7 years ago

Interventions

Neuraxial Analgesiadrug

This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).

Regional Block 1: Paravertebraldrug

This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

Perphenazinedrug

This randomized group will receive 8 mg of perphenazine orally preoperatively.

Aprepitantdrug

This randomized group will receive 40 mg of aprepitant orally preoperatively.

Dimenhydrinatedrug

This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.

Ondansetron 4 MGdrug

This randomized group will receive 4 mg of ondansetron orally.

Dexamethasonedrug

This randomized group will receive 4-5 mg of dexamethasone intravenously.

Regional Block 2: QL1drug

This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)